Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 1,377 shares at $30.88 ($43K) on 2023-02-08, disclosed to the SEC on 2023-02-10.
Open-market sale of $43k DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |